| Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma ME Juweid, S Stroobants, OS Hoekstra, FM Mottaghy, M Dietlein, ... Journal of clinical oncology 25 (5), 571-578, 2007 | 1679 | 2007 |
| Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced … M Herold, A Haas, S Srock, S Neser, KH Al-Ali, A Neubauer, G Dölken, ... Journal of Clinical Oncology 25 (15), 1986-1992, 2007 | 640 | 2007 |
| A systematic review of phase‐II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma A Glasmacher, C Hahn, F Hoffmann, R Naumann, H Goldschmidt, ... British journal of haematology 132 (5), 584-593, 2006 | 351 | 2006 |
| Prognostic value of positron emission tomography in the evaluation of post‐treatment residual mass in patients with Hodgkin's disease and non‐Hodgkin's lymphoma R Naumann, A Vaic, B Beuthien‐Baumann, J Bredow, J Kropp, T Kittner, ... British journal of haematology 115 (4), 793-800, 2001 | 269 | 2001 |
| Sequential monitoring of chimerism and detection of minimal residual disease after allogeneic blood stem cell transplantation (BSCT) using multiplex PCR amplification of short … C Thiede, M Bornhäuser, U Oelschlägel, C Brendel, R Leo, H Daxberger, ... Leukemia 15 (2), 293-302, 2001 | 259 | 2001 |
| Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma R Naumann, B Beuthien-Baumann, A Reiss, J Schulze, A Hänel, ... British journal of cancer 90 (3), 620-625, 2004 | 224 | 2004 |
| High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation N Gökbuget, N Basara, H Baurmann, J Beck, M Brüggemann, H Diedrich, ... Blood, The Journal of the American Society of Hematology 118 (13), 3504-3511, 2011 | 207 | 2011 |
| A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP … V Ballova, JU Rüffer, H Haverkamp, B Pfistner, HK Müller-Hermelink, ... Annals of Oncology 16 (1), 124-131, 2005 | 197 | 2005 |
| Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma HM Lokhorst, I Schmidt-Wolf, PS Van Der Holt, H Martin, R Barge, ... Haematologica 93 (1), 124-127, 2008 | 187 | 2008 |
| High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study) K Fritsch, B Kasenda, E Schorb, P Hau, J Bloehdorn, R Moehle, S Loew, ... Leukemia 31 (4), 846-852, 2017 | 161 | 2017 |
| Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation M Bornhäuser, U Schuller, G Pörksen, R Naumann, G Geissler, C Thiede, ... Transplantation 67 (4), 499-504, 1999 | 155 | 1999 |
| 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin’s lymphoma: results of a … M Sieber, H Bredenfeld, A Josting, T Reineke, U Rueffer, T Koch, ... Journal of clinical oncology 21 (9), 1734-1739, 2003 | 119 | 2003 |
| High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma F Morschhauser, F Kraeber-Bodéré, WA Wegener, JL Harousseau, ... Journal of Clinical Oncology 28 (23), 3709-3716, 2010 | 114 | 2010 |
| CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome F Taube, JA Georgi, M Kramer, S Stasik, JM Middeke, C Röllig, U Krug, ... Blood, The Journal of the American Society of Hematology 139 (1), 87-103, 2022 | 112 | 2022 |
| Results of a Prospective Randomised Open Label Phase III Study Comparing Rituximab Plus Mitoxantrone, Chlorambucile, Prednisolone Chemotherapy (R-MCP) Versus MCP Alone in … M Herold, R Pasold, S Srock, S Neser, D Niederwieser, A Neubauer, ... Blood, The Journal of the American Society of Hematology 104 (11), 584-584, 2004 | 107 | 2004 |
| A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma M Von Lilienfeld‐Toal, C Hahn‐Ast, K Furkert, F Hoffmann, R Naumann, ... European journal of haematology 81 (4), 247-252, 2008 | 99 | 2008 |
| Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin M Bornhäuser, C Thiede, U Schuler, U Platzbecker, J Freiberg-Richter, ... Bone marrow transplantation 26 (2), 119-125, 2000 | 97 | 2000 |
| Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma B Böll, P Borchmann, MS Topp, M Hänel, KS Reiners, A Engert, ... British journal of haematology 148 (3), 480-482, 2010 | 91 | 2010 |
| Single versus tandem high‐dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long‐term results from the phase III … EK Mai, A Benner, U Bertsch, P Brossart, A Hänel, V Kunzmann, ... British journal of haematology 173 (5), 731-741, 2016 | 74 | 2016 |
| Relapsed hodgkin lymphoma in older patients: a comprehensive analysis from the German hodgkin study group B Böll, H Goergen, N Arndt, J Meissner, SW Krause, R Schnell, ... Journal of clinical oncology 31 (35), 4431-4437, 2013 | 71 | 2013 |